The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. 
Introduction and Aim
Inflammatory bowel disease (IBD) including the two major forms, Crohn's disease and ulcerative colitis, is an inflammatory condition of the gastrointestinal tract characterized by periods of remission and intermittent relapses. The disease entity is associated with decreased quality of life, especially during relapses when treatment must be intensified. Currently, there are limited possibilities to predict the future disease course for an individual patient. Mucosal healing is presently the best prognostic marker, 1 being associated with reduced risk of clinical flares within the following two-year period. 2 IBD, however, is a life-long disease. Repeated colonoscopies are generally not accepted by patients and are associated with procedure-related risk and substantial cost.
Inflammatory markers in blood, such as C-reactive protein (CRP) and erythrocyte sedimentation rate, are useful to confirm ongoing mucosal inflammation but of less value to predict a future relapse, since elevated levels of these markers have not been found to precede a clinical flare. 3, 4 Faecal-based biomarkers, such as faecal calprotectin, might represent a better prognostic tool. 5, 6 Calprotectin accounts for approximately 40% of the cytosolic content of neutrophils and is released upon neutrophil activation. A correlation between the concentration of faecal calprotectin and endoscopic activity has consistently been reported in both ulcerative colitis and
Crohn's disease. [7] [8] [9] [10] [11] [12] Increased faecal calprotectin, measured at a single occasion, has also been associated with an increased risk of a future flare, especially within the following three months.
The reliance on single measurements may not be of great help given that IBD activity changes, sometimes rapidly, over time. Recently, post hoc analyses of clinical trials indicate that repeated measurements of faecal calprotectin every second or third month can predict future flares in selected patient populations, such as Crohn's disease patients treated with anti-TNF therapy and ulcerative proctitis patients treated with 5-ASA. 13, 14 However, any attempt to identify an 4 absolute cut-off will be limited by pronounced inter-assay differences [15] [16] [17] and will probably be disease and phenotype specific. Therefore, we aimed to assess whether consecutive measurements of faecal calprotectin every third month can be used to monitor unselected patients with IBD in clinical remission. More specifically, we wanted to evaluate whether change in faecal calprotectin between consecutively collected samples was associated with increased risk of future flare.
Materials and methods

Patients and study design
This is a 24-month prospective study where patients aged 18 years or older, with a confirmed diagnosis of Crohn's disease or ulcerative colitis, were consecutively screened for participation while attending the outpatient Gastroenterology Clinic at Örebro University Hospital. Patients in clinical remission based on the physician's global assessment 18 were eligible for inclusion irrespective of medication. Exclusion criteria were previous substantial surgical resections or any other systemic disease. Information on disease phenotype according to the Montreal classification 19 was extracted from the medical notes. Patients were asked to fill in a questionnaire and to provide a faecal sample at baseline. A faecal sample and a filled-in questionnaire was subsequently obtained every third month until the first clinical relapse or the end of the 24-month follow-up period. The questionnaire included questions on patient-reported outcome measures (e.g. number of stools/day, abdominal pain, blood and mucus in stool), daily rating of quality of life, 20 present IBD therapy, dietary habits, and use of antibiotics or NSAIDs .
Patients were followed with scheduled appointments according to clinical routine and instructed to contact the outpatient clinic if gastrointestinal symptoms consistent with a relapse of IBD occurred between appointments during follow up. Relapse was defined as increasing symptoms necessitating intensified medical therapy or surgery. If a patient did not provide a faecal sample at any of the three-month periods, a written reminder was sent.
Faecal calprotectin measurement
Faecal samples were collected in screw-capped plastic containers, sent the same day by mail to the laboratory, and stored at -70 C. Faecal calprotectin was extracted and analysed with ELISA according to the manufacturer's protocol (EK-CAL, Bühlmann Lab. AG, Switzerland) after all patients had ended the follow up. Consequently, the results of the faecal calprotectin measurements did not influence any clinical decisions. Faecal calprotectin levels were expressed as micrograms of faecal calprotectin per gram of faeces, with the limit of detection (LOD) 10 μg/g.
Statistics
Continuous variables with skewed distribution are presented as median and interquartile range (IQR). Differences between groups were compared using the Mann-Whitney U test, and frequencies were compared using the Chi-squared test. Variables that potentially affected sampling completeness were assessed using the logistic regression model. 
Results
Patients
In total, 169 patients were screened; 17 patients declined to participate, and 22 patients had active disease (Figure 1 ). Of the remaining 130 patients, 26 did not provide a faecal sample and were excluded from the analyses. Thus, 104 patients, Crohn's disease (n=49) and ulcerative colitis (n=55), entered the analysis and provided 525 faecal samples during the follow up, 6
samples of which were discarded due to inadequate packaging. A complete set of faecal samples was obtained from 61 patients, whereas 43 patients did not provide a faecal sample on one or 7 more occasions. Factors affecting sampling completeness were age at diagnosis (p0.005) and age at enrolment (p0.013), where patients younger than 40 years of age less often provided a complete sample set. A significant correlation between age at diagnosis and age at enrolment was observed (R0.585, p0.0001), necessitating the adjustment of main analysis for only one of these variables. To further explore the influence of baseline faecal calprotectin on time until relapse, patients were categorized into three groups based on the concentration of faecal calprotectin at baseline (<250 μg/g, 250-500 μg/g, >500 μg/g). A low baseline faecal calprotectin was associated with a lower cumulative relapse frequency, both at 3 months (p0.011) and 12 months (p0.014, Table   2 ). However, the association did not remain significant when the entire study period of 24 months was taken into account (p0.140). (Table 3 , Model 2). In other words, the most recent faecal calprotectin has the strongest association with the relapse. The risk of relapse and the time interaction remained significant when the analysis was performed for Crohn's disease and ulcerative colitis patients separately, (HR: 2.37; 95% CI: 1.46-3.87; p0.001) and (HR: 1.57; 95% CI: 1.11-2.23; p0.012), respectively.
Potential confounding lifestyle or treatment factors
To explore whether faecal calprotectin levels were systematically confounded by any additional variables other than those included in Model 2 (IBD therapy, patient characteristics, patient reported outcomes, diet, and use of antibiotics or NSAIDs), we used analysis of mixed models design to allow for dependence of faecal calprotectin within a diagnosis and an individual. Male sex and poor general well-being were associated with higher faecal calprotectin levels, (p0.03) and (p0.001), respectively (Supplement Table 1 
Discussion
In this prospective study, we explored whether the dynamics of faecal calprotectin were associated with the risk of a future flare in an unselected cohort of patients with IBD in clinical remission. We observed a 101% increased risk of clinical relapse within the following three-month period per unit increase in log2-transformed consecutive faecal calprotectin
measurements. An interaction between faecal calprotectin and time was also detected, corresponding to a 20% decrease in predicted risk of clinical relapse per three-month period since the sample was obtained. In clinical practice this would mean that a twofold increase of faecal calprotectin between two consecutive measurements with a three-month interval translates into a doubled risk of relapse within the following three months. The association between change in faecal calprotectin and risk of disease relapse is not constant over time. Should the patient not develop a clinical relapse within this period, the increased risk during the subsequent threemonth period is 20 % smaller. In other words, the most recent faecal calprotectin has the strongest association with relapse.
Numerous studies have revealed that faecal calprotectin correlates with the inflammatory activity in IBD, especially in patients with colorectal inflammation. 23 patients who experienced a relapse did so within the first three months. 3 Since then, many studies have confirmed this pivotal observation, but the proposed cut-off for identifying patients who are at increased risk of relapse differs between the studies. 9, 24, 25 One explanation for these cut-off differences are the pronounced inter-assay differences. [15] [16] [17] Another explanation is that cut-offs are disease and phenotype specific, since differences in the concentrations of FC have been reported between subgroups of patients with IBD, i.e. patients with ileal and colonic Crohn's disease. We did not try to find a specific cut-off value of faecal calprotectin, as this has been known to lead to results that are highly specific to the study sample and, therefore, unlikely to be generalized. Furthermore, it would have led to estimates that are less precise because of the decrease in the number of patients with higher levels. Faecal calprotectin is a highly dynamic biomarker of intestinal inflammation and is known to that the longer the time between bowel movements and the looser the stool consistency, the higher the concentrations of faecal calprotectin. 30 Associations between faecal calprotectin and age, obesity, physical inactivity, fibre intake, as well as vegetable consumption have also been reported in healthy individuals. 31 Therefore, we explored the influence of patient characteristics, patient reported outcome measures, use of antibiotics or NSAIDs, as well as dietary effects on faecal calprotectin in our dataset. NSAIDs have previously been associated with increased FC levels, [32] [33] [34] although the association did not really reach significance in our cohort. Increased concentrations of faecal calprotectin were observed in patients with poor daily rating of quality of life. It can be assumed that this may be caused by symptoms due to active bowel inflammation. However, independent associations with other dimensions of patient reported outcomes, like the number of bowel movements or blood in stool, could not be statistically confirmed in the entire IBD population, probably due to small sample size. In addition, an association between increased faecal calprotectin and male sex was also observed. This has been reported previously, 35 but the pathophysiologic explanation for the observed association between sex and concentration of faecal calprotectin can be only speculated on.
The major strength of this study was the prospective measurement of faecal calprotectin over a two-year period in consecutively recruited patients at an outpatient clinic. The fact that the measurements of faecal calprotectin were performed after completion of the study period and that the clinical decisions were not influenced by the observed results reduced the risk of differential bias. The observation that the results remained significant when adjusting for possible confounders, such as IBD therapy, patient characteristics, diet, and use of antibiotics or NSAIDs, further strengthen this study.
The fact that neither clinical remission at baseline nor clinical relapse during follow up were confirmed by endoscopy is a limitation of the study. However, repeated endoscopies are not accepted by patients and are associated with costs and risks. Similarly, co-monitoring of CRP was not regarded as feasible, since this would require admittance to health care every third month. Some patients were on corticosteroids at baseline, which might have influenced the relapse rate during the study period. The results might also be limited by the fact that 41% of the patients did not provide a faecal sample on one or several occasions. This problem was most pronounced among younger patients. However, none of the patients got feedback on their faecal calprotectin levels since faecal calprotectin was measured after all of the patients had completed their follow up. Another possible weakness of the study is that information on duration of clinical remission at baseline was not included in the analyses, since it is negatively associated with time to clinical relapse. 36 Our patient group is heterogeneous, comprising both Crohn's disease and ulcerative colitis patients, regardless of clinical characteristics, such as location, behaviour, and disease extent. Despite that, the predictive value of faecal calprotectin remained statistically significant even when patients with Crohn's disease and ulcerative colitis were analysed separately.
In conclusion, our data suggest that longitudinal monitoring of faecal calprotectin is informative in evaluating risk of relapse in IBD. By consecutive measurement of faecal calprotectin every third month, we quantified the relative risk of relapse associated with faecal calprotectin change 21 and observed attenuation of the risk across time. Future studies should evaluate whether early medical intervention is useful for the prevention of subsequent relapse in asymptomatic IBD patients with elevated faecal calprotectin levels and examine the cost-effectiveness of this monitoring regimen.
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